Cargando…
Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011–2014): a cross-sectional study
BACKGROUND: Although gabapentin has been licensed in the European Union only for neuropathic pain and epilepsy for patients who have partial seizures, it has also been prescribed in treatment for substance use disorders. Many studies report the potential risk of abuse of gabapentin by people with su...
Autores principales: | Van Baelen, Luk, De Ridder, Karin, Antoine, Jérôme, Gremeaux, Lies |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858131/ https://www.ncbi.nlm.nih.gov/pubmed/29560269 http://dx.doi.org/10.1186/s13690-018-0254-8 |
Ejemplares similares
-
Use of health care services by people with substance use disorders in Belgium: a register-based cohort study
por: Van Baelen, Luk, et al.
Publicado: (2021) -
COVID-19 and people who use drugs: Impact of the pandemic on general anxiety and depressive disorders among adults in Belgium
por: Van Baelen, Luk, et al.
Publicado: (2021) -
Longitudinal pharmacoepidemiological and health services research for substance users in treatment: protocol of the Belgian TDI-IMA linkage
por: Van Baelen, Luk, et al.
Publicado: (2018) -
Health care trajectories and medication consumption of substance users in treatment: linking TDI and IMA databases (Belgium)
por: De Ridder, Karin, et al.
Publicado: (2015) -
Prevalence of HCV among people who inject drugs in Brussels—a respondent-driven sampling survey
por: Van Baelen, Luk, et al.
Publicado: (2020)